Meta-Analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 511-517

  Li, Hui ^a   Liu, Ding Hui ^b   Chen, Lu Lu ^a   Zhao, Qi ^a   Yu, Yan Zhe ^a   Ding, Jing Jing ^a   Miao, Li Yun ^a   Xiao, Yong Long ^a   Cai, Hou Rong ^a   Zhang, De Ping ^a   Guo, Yu Biao ^c   Xie, Can Mao ^c  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CHRONIC LUNG DISEASE; HEARING IMPAIRMENT; HUMAN; LONG TERM CARE; META ANALYSIS; MICROBIOLOGICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; UNSPECIFIED SIDE EFFECT;

AZITHROMYCIN; CHRONIC DISEASE; HUMANS; LUNG DISEASES;

EID: 84891508976     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02067-13     Document Type: Article

References (25)

1. US Burden of Disease Collaborators. 2013. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors 1990-2010: burden of diseases, injuries, and risk factors. JAMA 310:591- 608. http://dx.doi.org/10. 1001/jama.2013.13805
2. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, Wan X, Yu S, Jiang Y, Naghavi M, Vos T, Wang H, Lopez AD, Murray CJ. 2013. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 381:1987-2015. http://dx.doi.org/10.1016/S0140-6736(13)61097-1
3. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR, COPD Clinical Research Network. 2011. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365:689-698. http://dx.doi.org/10.1056/NEJMoa1104623
4. Kanoh S, Rubin BK. 2010. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 23:590-615. http://dx.doi.org/10.1128/CMR.00078-09
5. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW, III, Macrolide Study Group. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 290:1749-1756. http://dx.doi.org/10.1001/jama.290.13.1749
6. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F, AZ0004 Azithromycin Study Group. 2010. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 303:1707- 1715. http://dx.doi.org/10.1001/jama.2010.563
7. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. 2012. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomized, double-blind, placebo-controlled trial. Lancet 380:660-667. http://dx.doi.org/10.1016/S0140-6736(12)60953-2
8. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, Verleden G, Demedts IK, Verhamme K, Delporte A, Demeyere B, Claeys G, Boelens J, Padalko E, Verschakelen J, Van Maele G, Deschepper E, Joos GF. 2013. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicenter randomized doubleblind placebo-controlled trial. Thorax 68:322-329. http://dx.doi.org/10 .1136/thoraxjnl-2012-202698
9. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. 2013. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial. JAMA 309:1251-1259. http://dx.doi.org/10.1001/jama.2013.1937
10. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. 2002. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomized trial. Thorax 57:212-216. http://dx.doi.org/10 .1136/thorax.57.3.212
11. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. 2002. Long term azithromycin in children with cystic fibrosis: A randomized, placebocontrolled crossover trial. Lancet 360:978-984. http://dx.doi.org/10.1016/S0140-6736(02) 11081-6
12. Hahn DL, Grasmick M, Hetzel S, Yale S, AZMATICS (AZithroMycin- Asthma Trial In Community Settings) Study Group. 2012. Azithromycin for bronchial asthma in adults: An effectiveness trial. J. Am. Board Fam. Med. 25:442-459. http://dx.doi.org/10.3122/jabfm.2012.04.110309
13. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. 2006. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 61:895-902. http://dx.doi.org/10 .1136/thx.2005.057950
14. Donath E, Chaudhry A, Hernandez-Aya LF, Lit L. 2013. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary disease. Respir. Med. 107:1385-1392. http://dx.doi.org/10.1016/j.rmed.2013.05.004
15. Reiter J, Demirel N, Mendy A, Gasana J, Vieira ER, Colin AA, Quizon A, Forno E. 2013. Macrolides for the long-term management of asthma: A meta-analysis of randomized clinical trials. Allergy 68:1040-1049. http://dx.doi.org/10.1111/all.12199
16. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. 1991. Long-term low-dose administration of erythromycin to patients with diffuse panbrochiolitis. Respiration 58:145-149. http://dx.doi.org/10 .1159/000195915
17. Feola DJ, Garvy BA, Cory TJ, Birket SE, Hoy H, Hayes D, Jr, Murphy BS. 2010. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. Antimicrob. Agent Chemother. 54:2437-2447. http://dx.doi.org/10.1128/AAC.01424-09
18. Hodge S, Reynolds PN. 2012. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. Respirology 17:802-807. http://dx.doi.org/10.1111/j.1440-1843.2012.02135.x
19. Gielen V, Johnston SL, Edwards MR. 2010. Azithromycin induces antiviral responses in bronchial epithelial cells. Eur. Respir. J. 36:646-654. http://dx.doi.org/10.1183/09031936.00095809
20. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, Bowden AR, Newton SM, Kampmann B, Helm J, Jones A, Haworth CS, Basaraba RJ, DeGroote MA, Ordway DJ, Rubinsztein DC, Floto RA. 2011. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J. Clin. Invest. 121:3554-3563. http://dx.doi.org/ 10.1172/JCI46095
21. Binder AM, Adjemian J, Olivier KN, Prevots DR. 2013. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am. J. Respir. Crit. Care Med. 188:807-812. http://dx.doi.org/10.1164/rccm.201307-1200OC
22. Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, Taylor J, Singanayagam A, Hill AT, Chalmers JD. 2013. Cardiovascular events after clarithromycin use in lower respiratory tract infections: Analysis of two prospective cohort studies. BMJ 346:f1235. http://dx.doi.org/10.1136/bmj.f1235
23. Lutz L, Pereira DC, Paiva RM, Zavascki AP, Barth AL. 2012. Macrolidesdecrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm. BMC Microbiol. 12:196. http://dx.doi.org/10.1186/1471-2180-12-196
24. Hare KM, Singleton RJ, Grimwood K, Valery PC, Cheng AC, Morris PS, Leach AJ, Smith-Vaughan HC, Chatfield M, Redding G, Reasonover AL, McCallum GB, Chikoyak L, McDonald MI, Brown N, Torzillo PJ, Chang AB. 2013. Longitudinal nasopharyngeal carriage and antibiotic resistance of respiratory bacteria in indigenous Australian and Alaska native children with bronchiectasis. PLoS One 8:e70478. http://dx.doi.org/10.1371/journal.pone.0070478
25. Roberts MC, Soge OO, No DB. 2011. Characterization of macrolide resistance genes in Haemophilus influenzae isolated from children with cystic fibrosis. J. Antimicrob. Chemother. 66:100-104. http://dx.doi.org/10.1093/jac/ dkq425